RARE-07. EFFICACY AND SAFETY OF LAROTRECTINIB IN PEDIATRIC PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION-POSITIVE PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS

BACKGROUND: NTRK gene fusions are oncogenic drivers in various CNS and non-CNS tumors. Larotrectinib is a highly selective TRK inhibitor approved to treat patients with TRK fusion cancer, with an objective response rate (ORR) of 78% across multiple non-CNS cancers (McDermott et al, ESMO 2020). We re...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Neuro Oncol
Huvudupphovsmän: Perreault, Sébastien, Doz, François, Geoerger, Birgit, Nysom, Karsten, Øra, Ingrid, Boni, Valentina, Chisholm, Julia, DuBois, Steven G, Gerber, Nicolas U, Goto, Hiroaki, Grilley-Olson, Juneko E, Hansford, Jordan R, Kang, Hyoung Jin, Capra, Michael, Schulte, Johannes H, Stefanowicz, Joanna, Tahara, Makoto, Ziegler, David S, Norenberg, Ricarda, Dima, Laura, De La Cuesta, Esther, Laetsch, Theodore W, van Tilburg, Cornelis M
Materialtyp: Artigo
Språk:Inglês
Publicerad: Oxford University Press 2021
Ämnen:
Rare Tumors/Other
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC8168097/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noab090.168
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk